Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A129838-1mg | 1mg | In stock | $26.90 | |
A129838-5mg | 5mg | In stock | $102.90 | |
A129838-10mg | 10mg | In stock | $149.90 | |
A129838-25mg | 25mg | In stock | $252.90 | |
A129838-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $454.90 |
Potent, selective CB 2 agonist
Synonyms | UNII-DLM851L3RD | NCGC00165726-01 | (2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone | SW219858-1 | HMS542C22 | CS-0011638 | 3-[(2-iodo-5-nitrophenyl)carbonyl]-1-[(1-methylpiperidin-2-yl)methyl]-1H-indole | AKOS016004972 | |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | AM-1241 is a protean agonist of CB2 based on the different effect observed in various assays (calcium influx, extracellular signal-regulated kinase (ERK) phosphorylatin and cAMP measurement)) and on the switch from neutral antagonism to agonism in the cAM |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of CB 2 receptor |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | (2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone |
---|---|
INCHI | InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3 |
InChi Key | ZUHIXXCLLBMBDW-UHFFFAOYSA-N |
Canonical SMILES | CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=C(C=CC(=C4)[N+](=O)[O-])I |
Isomeric SMILES | CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=C(C=CC(=C4)[N+](=O)[O-])I |
WGK Germany | 3 |
Alternate CAS | 444912-48-5 |
PubChem CID | 10141893 |
MeSH Entry Terms | AM 1241;AM1241 |
Molecular Weight | 503.33 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2103414 | Certificate of Analysis | Aug 04, 2023 | A129838 |
K2103416 | Certificate of Analysis | Aug 04, 2023 | A129838 |
K2103424 | Certificate of Analysis | Aug 04, 2023 | A129838 |
K2103425 | Certificate of Analysis | Aug 04, 2023 | A129838 |
K2103427 | Certificate of Analysis | Aug 04, 2023 | A129838 |
Solubility | DMSO 101 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
---|
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H334:May cause allergy or asthma symptoms or breathing difficulties if inhaled |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P284:[In case of inadequate ventilation] Wear respiratory protection. P271:Use only outdoors or in a well-ventilated area. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. P342+P316:If experiencing respiratory symptoms: Get emergence medical help immediately. |
WGK Germany | 3 |
1. Niu J et al.. (2017) Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y12and P2Y13receptors in neuropathic pain rats.. J Neuroinflammation, 14 (185). [PMID:28899427] |
2. Zhou S et al.. (2021) Cannabinoid receptor 2 plays a central role in renal tubular mitochondrial dysfunction and kidney ageing.. J Cell Mol Med, 25 (18): (8957-8972). [PMID:34414658] |
3. Li MH et al.. (2017) Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain.. J Neurosci, 37 (3): (626-636). [PMID:28100744] |
4. Abd El-Rahman SS & Fayed HM. (2022) Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NF?Bp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats.. PLoS One, 17 (3): (e0265961). [PMID:35349580] |
5. Ali AM et al.. (2021) Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide.. Chem Biol Interact, 336 (109398). [PMID:33503444] |